Onkologie. 2010:4(3):189-195

Treatment of chronic myeloid leukemia in adults in 2010

Jaroslava Voglová
II. interní klinika –, oddělení klinické hematologie, LF UK a FN Hradec Králové

In the past decade the management strategies of patients with chronic myeloid leukemia have been completely changed. Imatinib

became the standard front-line therapy in patients with newly diagnosed chronic-phase CML. Allogeneic stem cell transplantation in

CML patients is increasingly deferred despite its curative potential. Second generation tyrosine kinase inhibitors dasatinib and nilotinib

together with the improved molecular monitoring of residual leukemia and the identification of BCR-ABL1 mutations with wide spectrum

of sensitivity to tyrosine kinase inhibitors make possible the tailoring of CML treatment. Current recommendations for the management

of CML are reviewed.

Keywords: chronic myeloid leukemia, therapy, tyrosine kinase inhibitors, stem cell transplantation

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Voglová J. Treatment of chronic myeloid leukemia in adults in 2010. Onkologie. 2010;4(3):189-195.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Padmanabhan S, Ravella S, Curiel T, Giles F. Current status of therapy for chronic myeloid leukemia: a review of drug development. Future Oncol. 2008; 4(3): 359-377. Go to original source... Go to PubMed...
    2. Indrák K. Komentář ke studii Nilotinib, vysoce selektivní inhibitor BCR-ABL tyrosinkinázy, je účinný u nemocných s Ph+ chronickou myeloidní leukemií v chronické fázi, kteří jsou rezistentní k imatinibu nebo jej nesnášejí. Farmakoterapie 2008; 4: 462-463.
    3. Cortes JE, Talpaz M, O´Brien S, et al. Staging of chronic myeloid leukemia in imatinib era. Cancer 2006; 106: 1306-1315. Go to original source... Go to PubMed...
    4. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in, ,good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799. Go to original source...
    5. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Journal of NCI 1998; 90: 850-858. Go to original source...
    6. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin N Am 2004; 18: 569-584. Go to original source... Go to PubMed...
    7. Sears DA. History of treatment of chronic myelocytic leukemia. AM J Med SCI 1988; 296: 85-86. Go to original source... Go to PubMed...
    8. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521. Go to PubMed...
    9. O´Brien SG, Guilhot F, Goldman JM, et al. International randomized study of Interferon versus STI571 (IRIS) 7-year followup: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients with newly diagnose chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib (IM). Blood 2008; 112: 76. Go to original source...
    10. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28: 424-430. Go to original source... Go to PubMed...
    11. De Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-totreat analysis. J Clin Oncol 2008; 26: 3308-3309. Go to original source... Go to PubMed...
    12. Apperley JF, Part I. Mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 2007; 8: 1018-1029. Go to original source... Go to PubMed...
    13. Šťastný M, Machová Poláková K, Klamová H a kol. Analýza mutací BCR-ABL u CML pacientů rezistentních k imatinibu umožňuje poskytnout, ,terapii šitou na míru". Transfuze Hematol. dnes 2010; 16: 47-54.
    14. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2009; 24: 6-12. Go to original source... Go to PubMed...
    15. Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 2008; 26: 7009. Go to original source...
    16. Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hammerschlak N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a standard dose of 400 to 600 milligrams daily. Cancer 2009; 115: 4136-4147. Go to original source... Go to PubMed...
    17. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204-3212. Go to original source... Go to PubMed...
    18. Shah NP, Kim DW, Kantarjian H, et al. Potent transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformationfree survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010; 95: 232-240. Go to original source... Go to PubMed...
    19. Kantarjian HM, Giles F, Bhalla KN, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008; 112: 1112. Go to original source...
    20. Swords R, Mahalingam RD, Padmanabhan S, Carew J, Giles F. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Design, Development and Therapy 2009; 3: 89-101. Go to original source... Go to PubMed...
    21. Mauro MJ. Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Cancer Control 2009; 16: 108-121. Go to original source... Go to PubMed...
    22. Gratwohl A, Hermans J, Goldman JM. Risk assesment for patiens with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092. Go to original source... Go to PubMed...
    23. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820. Go to original source... Go to PubMed...
    24. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051. Go to original source... Go to PubMed...
    25. Goldman JM. Initial treatment for patients with CML. Hematology 2009; American Society of Hematology education Program Book: 453-460. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.